‘Entecavir,’ a hepatitis type B treatment, became the target of priority sales for the 2nd time
A product approval for priority sales has been made for entecavir, a type B hepatitis treatment, which will be expired in substance approval on the coming October.
The Ministry of Food and Drug Safety has granted approvals for a few products of pharmaceutical companies on the 29th.
The priority...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
